| reparixin (DF 1681Y) / Dompe |
| Terminated | 3 | 409 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 09/24 | | |
2013-002244-86: extention up to 3 years of the follow-up of patients treated with reparixin under protocol REP0110. estensione a 3 anni del follow-up dei pazienti trattati con Reparixin nello studio REP0110 |
|
|
| Ongoing | 2 | 3 | Europe | Reparixin, DF 1681Y, | Dompé s.p.a., Dompé s.p.a. | patients who have received pancreatic islet transplantation pazienti che hanno ricevuto trapianto di isole pancreatiche | | | | |
2021-000382-32: A study efficacy and safety of reparixin tablets in cancer related fatigue for breast cancer patients undergoing chemotherapy |
|
|
| Not yet recruiting | 2 | 76 | Europe | Reparixin, [Reparixin], Tablet | Dompé farmaceutici s.p.a., DOMPé FARMACEUTICI S.P.A., Dompé farmaceutici s.p.a., Dompé farmaceutici S.p.A. | Cancer related fatigue in patients with locally advanced or metastatic breast cancer, Cancer related fatigue in patients with breast cancer, Diseases [C] - Cancer [C04] | | | | |
2022-001612-25: Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy in adult patients with Acute Respiratory Distress Syndrome Studio di fase II, multicentrico, randomizzato, in doppio cieco e controllato con placebo volto a valutare l'efficacia e la sicurezza di reparixin come terapia aggiuntiva in pazienti adulti con sindrome da distress respiratorio acuto |
|
|
| Not yet recruiting | 2 | 66 | Europe | Reparixin, [DF 1681Y], Tablet | DOMPé FARMACEUTICI S.P.A., Dompè farmaceutici s.p.a. | Acute Respiratory Distress Syndrome Sindrome da distress respiratorio acuto, Serious lung condition that causes low blood oxygen Grave condizione polmonare che causa un basso livello di ossigeno nel sangue, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 2 | 66 | Europe, US | Reparixin 600mg, REP, Matching Placebo, Control | Dompé Farmaceutici S.p.A | Acute Respiratory Distress Syndrome, Adult | 08/25 | 08/25 | | |
NCT05835466: Reparixin in Patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) |
|
|
| Recruiting | 2 | 26 | US | reparixin | Icahn School of Medicine at Mount Sinai, Dompé Farmaceutici S.p.A | Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis (PV-MF) | 12/25 | 12/27 | | |
